Research & Development
Aratana Therapeutics to unveil US FDA approved NOCITA in 10 ml Vial by autumn 2019
12 June 2019 -

Pet therapeutics company Aratana Therapeutics Inc (Nasdaq:PETX) reported on Monday the receipt of approval from the US Food and Drug Administration's Center for Veterinary Medicine (CVM) for an additional vial size in 10 ml for NOCITA (bupivacaine liposome injectable suspension) for the management of pain in dogs and cats.

Currently, NOCITA is available in a 20 ml vial size only and the NOCITA in 10 ml vial is expected to be launched commercially by the autumn this year, added the company.

According to the company, NOCITA is US FDA-approved for single-dose infiltration into the surgical site to provide local post-operative analgesia for cranial cruciate ligament surgery in dogs and as a peripheral nerve block to provide regional post-operative analgesia following owner-elected onychectomy in cats.

The company said NOCITA (bupivacaine liposome injectable suspension) is for local infiltration injection in dogs as well as used as a peripheral nerve block in cats.



Related Headlines